Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

Benzinga Newsdesk www.benzinga.com Negative 71.9%

Neg 71.9% Neu 0% Pos 0%

Wedbush analyst Laura Chico reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price target.